Evidenzbasierte Sprachtherapie bei Morbus Parkinson: LSVT LOUD

Die meisten Patient*innen mit Morbus Parkinson entwickeln im Laufe ihrer Erkrankung Stimm- und Sprechstörungen. Die Wirksamkeit des Stimm- und Sprechtherapieverfahrens LSVT LOUD ist hier nachgewiesen. Auch sollte bereits vor neurochirurgischer Therapie mittels tiefer Hirnstimulation im Bereich des Nucleus subthalamicus eine LSVT-LOUD-Therapie durchgeführt werden, um einer möglichen Verschlechterung der Sprechfähigkeit bereits prophylaktisch entgegen zu wirken.

Abstract

Most patients with Parkinsonʼs disease develop voice and speech disorders in the course of their illness. The effectiveness of the voice and speech therapy method LSVT LOUD has been described here. The extensive research behind this voice treatment, combined with successful clinical implementation globally, demonstrate the potential for LSVT LOUD to have a positive impact on quality of life for many individuals with neurological voice and speech disorders.

Schlüsselwörter

Morbus Parkinson - Sprachtherapie - LSVT LOUD - Stimmstörung - Sprechstörung

Key Words

Parkinson's disease - speech therapy - LSVT LOUD - Dysarthria - dysphonia

Publication History

Article published online:
29 November 2022

• Literatur

• 1 Miller N, Allcock L, Jones D. et al. Prevalence and pattern of perceived intelligibility changes in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2007; 78: 1188-1190
• 2 Schalling E, Johansson K, Hartelius L. Speech and communication changes reported by people with Parkinson’s disease. Folia Phoniatr Logopaed 2017; 69: 131-141
• 3 Logemann J, Fisher H, Boshes B. et al. Frequency and co-occurrence of vocal tract dysfunctions in the speech of a large sample of Parkinson individuals. J Speech Hear Disord 1978; 42: 47-57
• 4 Duffy JR. Motor speech disorders: Substrates, differential diagnosis, and management. 4th ed. Amsterdam: Elsevier Mosby; 2020
• 5 Clark J, Adams S, Dykstra A. et al. Loudness perception and speech intensity control in Parkinsonʼs disease. J Commun Disord 2014; 51: 1-12
• 6 Arnold C, Gehrig J, Gispert S. et al. Pathomechanisms and compensatory efforts related to Parkinsonian speech. Neuroimage Clin 2013; 4: 82-97
• 7 Miller N, Noble E, Jones D. et al. Life with communication changes in Parkinsonʼs disease. Age Ageing 2006; 35: 235-239
• 8 Miller N, Noble E, Jones D. et al. How do I sound to me? Perceived changes in communication in Parkinsonʼs disease. . Clin Rehabil 2008; 22: 14-22
• 9 Miller N. Speech, voice and language in Parkinson’s disease: changes and interventions. Neurodegener Dis Manag 2012; 2: 279-289
• 10 Pinto S, Ozsancak C, Tripoliti E. et al. Treatments for dysarthria in Parkinson’s disease. Lancet Neurol 2004; 3: 547-556
• 11 Trail M, Fox C, Ramig L. et al. Speech treatment for Parkinson’s disease. NeuroRehabilitation 2005; 20: 205-221
• 12 Tripoliti E, Zrinzo L, Martinez-Torres I. et al. Effects of subthalamic stimulation on speech of consecutive patients with Parkinson disease. Neurology 2011; 76: 80-86
• 13 Mollaei F, Shiller DM, Gracco VL. Sensorimotor adaptation of speech in Parkinsonʼs disease. Mov Disord 2013; 28: 1668-1674
• 14 Fox C, Morrison C, Ramig L. et al. Current perspectives on the Lee Silverman Voice Treatment (LSVT) for individuals with idiopathic Parkinson disease. Am J Speech Lang Pathol 2002; 11: 111-123
• 15 Ramig L, Sapir S, Countryman S. et al. Intensive voice treatment (LSVT) for patients with Parkinson’s disease: A 2 year follow up. J Neurol Neurosurg Psychiatry 2001; 71: 493-498
• 16 Bryans LA, Palmer AD, Anderson S. The impact of Lee Silverman Voice Treatment (LSVT LOUD) on voice, communication, and participation: Findings from a prospective, longitudinal study. J Commun Disord 2021; 89: 106031
• 17 Ramig LO, Halpern A, Spielman J. et al. Speech treatment in Parkinsonʼs Disease: Randomized controlled trial (RCT). Mov Disord 2018; 33: 1777-1791
• 18 Ramig L, Sapir S, Fox C. et al. Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson’s disease: A comparison with untreated patients and normal age-matched controls. Mov Disord 2001; 16: 79-83
• 19 Halpern A, Ramig L, Matos C. et al. Innovative technology for the assisted delivery of intensive voice treatment (LSVT LOUD) for Parkinson disease. Am J Speech Lang Pathol 2012; 21: 354-367
• 20 Narayana S, Franklin C, Peterson E. et al. Immediate and long-term effects of speech treatment targets and intensive dosage on Parkinsonʼs disease dysphonia and the speech motor network: Randomized controlled trial. Human Brain Mapping 2022;
• 21 Smith ME, Ramig L, Dromey C. et al. Intensive voice treatment in Parkinson disease: Laryngostroboscopic findings. J Voice 1995; 9: 453-459
• 22 Levy ES, Moya-Galé G, Chang Y. et al. The effects of intensive speech treatment on intelligibility in Parkinsonʼs disease: A randomised controlled trial. EClinicalMedicine 2020; 24: 100429
• 23 Schulz G, Halpern A, Spielman J. et al. Single word intelligibility of individuals with Parkinsonʼs disease in noise: Pre-specified secondary outcome variables from a randomized control trial (RCT) comparing two intensive speech treatments (LSVT LOUD vs. LSVT ARTIC). Brain Sci 2021; 11: 857
• 24 Baumgartner C, Sapir S, Ramig L. Voice quality changes following phonatory-respiratory effort treatment (LSVT) versus respiratory effort treatment for individuals with Parkinson disease. J Voice 2001; 15: 105-114
• 25 Sapir S, Spielman J, Ramig L. et al. Effects of intensive voice treatment (LSVT) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: Acoustic and perceptual findings. J Speech Lang Hear Res 2007; 50: 899-912
• 26 Dumer AI, Oster H, McCabe D. et al. Effects of the Lee Silverman Voice Treatment on hypomimia in Parkinson’s disease. J Int Neuropsychol Soc 2014; 20: 302-312
• 27 Narayana S, Fox PT, Zhang W. et al. Neural correlates of efficacy of voice therapy in Parkinson’s disease identified by performance–correlation analysis. Hum Brain Mapp 2010; 31: 222-236
• 28 Theodoros DG, Hill AJ, Russell RG. Clinical and quality of life outcomes of speech treatment for Parkinson’s disease delivered to the home via telerehabilitation: A noninferiority randomized controlled trial. Am J Speech Lang Pathol 2016; 25: 214-232
• 29 LSVT Global. LSVT LOUD-Clinicians. www.lsvtglobal.com
• 30 Sauvageau VM, Roy JP, Langlois M. et al. Impact of the LSVT on vowel articulation and coarticulation in Parkinsonʼs disease. Clin Linguist Phon 2015; 29: 424-440
• 31 Baumann A, Nebel A, Granert O. et al. Neural correlates of hypokinetic dysarthria and mechanisms of effective voice treatment in Parkinson disease. Neurorehabil Neural Repair 2018; 32: 1055-1066
• 32 Whitehill TL, Kwan L, Lee FPH. et al. Effect of LSVT on lexical tone in speakers with Parkinson’s disease. Parkinsons Dis 2011; 2011: 897494
• 33 Nakayama K, Yamamoto T, Oda C. et al. Effectiveness of Lee Silverman Voice Treatment LOUD on Japanese-speaking patients with Parkinson’s disease. J Rehabil Res Pract 2020; 2020: 6585264
• 34 Saffarian A, Amiri Shavaki Y, Shahidi GA. et al. Lee Silverman voice treatment (LSVT) mitigates voice difficulties in mild Parkinsonʼs disease. Med J Islam Repub Iran 2019; 13: 5
• 35 Moya-Galé G, Goaders A, Bayes À. et al. The effects of intensive speech treatment on conversational intelligibility in Spanish speakers with Parkinsonʼs disease. Am J Speech Lang Pathol 2018; 27: 154-165
• 36 Mahler L, Ramig LO. Intensive treatment of dysarthria secondary to stroke. Clin Linguist Phon 2012; 26: 681-694
• 37 Moya-Galé G, Galgano J, Ferrone C. et al. LSVT LOUD applied to an adult with cerebral palsy: Acoustic findings. Commun Disord Quarterly 2021; 43: 119-127
• 38 Sapir S, Pawlas A, Ramig L. et al. Effects of intensive phonatory-respiratory treatment (LSVT) on voice in individuals with multiple sclerosis. J Med Speech Lang Pathol 2001; 9: 35-45
• 39 Sapir S, Spielman J, Ramig L. et al. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on ataxic dysarthria: A case study. Am J Speech Lang Pathol 2003; 12: 387-399
• 40 Bakhtiari R, Cummine J, Reed A. et al. Changes in brain activity following intensive voice treatment in children with cerebral palsy. Hum Brain Mapp 2017; 38: 4413-4429
• 41 Boliek CA, Fox CM. Therapeutic effects of intensive voice treatment (LSVT LOUD) for children with spastic cerebral palsy and dysarthria: A phase I treatment validation study. Int J Speech Lang Pathol 2017; 19: 601-615
• 42 Boliek C, Halpern A, Herandez K. et al. Intensive Voice Treatment (LSVT LOUD) for Children with Down Syndrome. Phase 1 Outcomes. J Speech Lang Hear Res 2022; 65: 1228-1262
• 43 Tripoliti E, Limousin P, Foltynie T. et al. Predictive factors of speech intelligibility following subthalamic nucleus stimulation in consecutive patients with Parkinson’s disease. Mov Disord 2014; 29: 532-538
• 44 Astrom M, Tripoliti E, Hariz MI. et al. Patient-specific model-based investigation of speech intelligibility and movement during deep brain stimulation. Stereotact Funct Neurosurg 2010; 88: 224-233
• 45 Mahlknecht P, Akram H, Georgiev D. et al. Pyramidal tract activation due to subthalamic deep brain stimulation in PD. Mov Disord 2017; 32: 1174-1182
• 46 Tripoliti E, Zrinzo L, Martinez-Torres I. et al. Effects of contact location and voltage amplitude on speech and movement in bilateral subthalamic nucleus deep brain stimulation. Mov Disord 2008; 23: 2377-2383
• 47 Moreau C, Pennel-Ployart O, Pinto S. et al. Modulation of dysarthropneumophonia by low-frequency STN-DBS in advanced Parkinson’s Disease. Mov Disord 2011; 26: 659-663
• 48 Wertheimer J, Gottuso AY, Nuno M. et al. The impact of deep brain stimulation on speech in individuals with Parkinson’s disease: the paient’s perspective. Parkinsonism Relat Disord 2013; 10: 1065-1070
• 49 Frost E, Tripoliti E, Hariz MI. et al. Self-perception of speech changes in patients wit PD following deep brain stimulation of the subthalamic nucleus. Int J Speech Lang Pathol 2010; 12: 399-404
• 50 Spielman J. et al. Intensive voice treatment (LSVTLOUD) for Parkinsonʼs disease following deep brain stimulation of the subthalamic nucleus. Journal of Communication Disorders 2011; 44: 688-700
• 51 Liotti M. et al. Hypophonia in Parkinsonʼs disease: Neural correlates of voice treatment revealed by PET. Neurology 2003; 60: 432-440
• 52 Tsuboi T, Watanabe H, Tanaka Y. et al. Characteristic laryngoscopic findings in Parkinson’s disease patients after subthalamic nucleus deep brain stimulation and its correlation with voice disorder. J Neural Trasm 2015; 122: 1663-1672
• 53 Alberts JL. et al. Are two leads always better than one: An emerging case for unilateral subthalamic deep brain stimulation in Parkinsonʼs disease. Experimental Neurology 2008; 214 Issue 1
• 54 Frankemolle AM. et al. Reversing cognitive -motor impairments in Parkinsonʼs disease patients using a computational modelling approach to deep brain stimulation programming. Brain 2010; 133: 746-761